Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hetrombopag olamine for chemoradiation-induced thrombocytopenia
ChiCTR2200057846Phase 4Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of hetrombopag in Thrombocytopenia, sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Percentage of patients whose platelet count returned to ≥ 100×10^9/L during treatment. Planned start Apr 2022; status: not yet recruiting.
02
Drugs
hetrombopag
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on ChiCTR2200057846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057846.